Perseus Biomics: EIC Accelerator Bet on Imaging the Gut Microbiome

In June 2021, a small Belgian company asked the European Innovation Council to fund a machine that would read gut bacteria without sequencing their DNA. Perseus Biomics won. Its project, Perseus MAP, received a €2.5 million grant and a place in the EIC Fund portfolio, and it promised the EU a service lab, a network of satellite labs and finally portable analysers processing 300,000 microbiome profiles a year.

Five years later, the machine exists. It weighs 60 kilograms, handles eight samples per run and is sold through an early-access programme. The company's own filings tell the rest of the story: losses have grown every year, equity has halved in twelve months, and debt is climbing again. The EU's project database still holds no final results.

This is the first in a series that follows EIC Accelerator winners after the money arrives. The question is simple: what did the European taxpayer get?

What Perseus Biomics Does Today

Perseus Biomics sells microbiome profiling in two forms. Customers can send samples to its laboratory in Leuven, a service the company says it launched commercially in 2024, or they can apply for one of the "limited slots" for its MetaMAP benchtop device, which the company offers to "pioneering teams in the EU". MetaMAP is not listed with a price, and the product page makes no mention of CE-IVD marking, which an in-vitro diagnostic device needs under the EU IVD Regulation before it can be sold for clinical diagnosis.

The target customers are not hospitals. The company pitches MetaMAP at nutrition and wellness programmes, probiotic and food producers, and therapeutics developers. The only named commercial users in the public record are the probiotics firm AB-Biotics, which uses the service for strain tracking, and an unnamed sourdough bread maker, both cited by NutraIngredients in December 2024. The Belgian food group Puratos is listed as a partner by Belgian Research.

The company is registered as active and filed accounts for 2025. Its latest news item, the MetaMAP launch, dates from June 2025. The Belgian Official Gazette recorded a move of the registered office in March 2025 and changes among directors in March and September 2025.

The Technology: Photographing DNA Instead of Reading It

Standard microbiome analysis relies on DNA sequencing: extracting the genetic material from a stool sample and reading it letter by letter, either for one marker gene (16S) or for everything present (shotgun metagenomics). Perseus argues that this is the wrong tool for the job. Sequencing-based results "usually take months", its R&D director told NutraIngredients.

Perseus takes a different route called optical mapping. Long DNA fragments are stretched out on a surface and tagged with fluorescent labels at specific sequence sites. Under a microscope, each fragment glows in a pattern of dots, a barcode unique to the organism it came from. Software matches those barcodes against a reference library of known genomes. The company calls the method DynaMAP. No amplification and no sequencing library are needed.

The strongest evidence for the method is a preprint posted on bioRxiv in December 2024 by researchers from Perseus and KU Leuven. It reports a turnaround of about 6.5 hours, strain separation at more than 99.5% average nucleotide identity, and relative-abundance errors of "about 1-5%" against shotgun sequencing on real samples. The reference database holds 4,992 genomes covering 2,805 species. The underlying optical mapping data was published openly in October 2025, which is to the authors' credit.

The same paper is candid about the limits. The validation rests on a commercial mock community, a five-species calibration mix and five human stool samples. Some common gut bacteria, such as Phocaeicola vulgatus, were notably underestimated, and yeasts were underrepresented. Most important for a technology sold on precision, it cannot see as deep as sequencing.

Nearly two years after posting, no peer-reviewed journal version of the preprint could be found. The paper declares no competing interests, although its authors include the company's R&D director and two of its vice presidents.

What the EIC Project Promised, and What CORDIS Shows

Perseus MAP ran from 1 October 2021 to 30 September 2023 under the 2021 Accelerator challenge for Strategic Digital and Health Technologies, with total costs of €3,575,740 and an EU contribution of €2,500,000, according to CORDIS. The objective was explicit: "starting with a central service lab, deploying satellite labs, and finally producing portable units for the microbiomics mass market", with in-house capacity of 300,000 profiles a year aimed at a €2.5 billion market.

CORDIS publishes a single periodic report summary. It describes a working prototype analyser at headquarters "currently undergoing benchmarking", with automated sample handling, consumables through a first industrialisation phase and remote monitoring for global deployment. The project's results page lists no results, no deliverables and no publications. Measured against its own stated plan, the record looks like this:

1. Automated analyser prototypeDeliveredPrototype reported on CORDIS; MetaMAP launched with the Leuven engineering firm Comate in June 2025.
2. Central service labDeliveredProfiling service launched in 2024, a year after the project ended, with named users including AB-Biotics.
3. Network of satellite labsNo evidenceNo satellite lab is named anywhere in the company's materials or in press coverage.
4. Portable units for a mass marketNot deliveredMetaMAP measures 60 × 70 × 50 cm and weighs 60 kg, according to Clinical Laboratory. It is a benchtop instrument in early access.
5. 300,000 profiles a yearNo evidenceNo sample volumes have been disclosed. The accounts do not report turnover.
6. Independent scientific validationPartialPreprint and open data exist; no peer-reviewed publication.
7. Public final reportingMissingThree years after closure, CORDIS shows one periodic summary and an empty results page.

The capacity target deserves a closer look, because it was the headline number. At the published specification, the machine the project produced cannot come close to it on its own.

None of this means the project failed. EIC Accelerator grants fund development to market readiness, not market success, and a two-year project that ends with a functioning instrument has done the core of what a grant can do. The gap is between what was promised in the proposal and what can be checked today, and on the ambitious half of that promise the public record is silent.

What Perseus Has Achieved Since the Award

The achievements are real. The company built a working instrument with a European hardware partner, published its method with open data, joined a second EU project and won recognition from the industry. It was named one of three Probiota 2025 Pioneers and presented DynaMAP on stage at the IPA World Congress in Copenhagen in February 2025.

The second EU grant is significant. Perseus is one of 14 partners in OPADE, a €10 million Horizon Europe health project that is looking for gut and other biomarkers predicting how patients with major depression respond to antidepressants. Perseus's share is €694,375, and the project runs until May 2027. That puts the company's direct EU grant funding at about €3.19 million, before any EIC Fund equity.

The Money: Rising Losses, Falling Equity

Belgian companies must file annual accounts, and Perseus's filings, reported consistently by Companyweb and Staatsbladmonitor, are the most reliable public source on how the company is doing. They show a business that is spending faster each year.

At the end of 2022 equity had fallen to €33,609, less than 1% of a €4.3 million balance sheet, with €4.27 million of debt. In 2023 the picture reversed: the Official Gazette published a capital increase and a change of legal form in June, equity rose to €4.65 million and debt fell by €3.66 million. In 2024 equity rose by exactly €2 million more than the year's loss consumed, and the Gazette published a change to the company's capital in September.

2025 broke the pattern. Equity fell from €4.52 million to €2.06 million, a drop that matches the year's €2,463,978 loss to the euro. No new equity was raised. Debt rose by €2.24 million to €3.19 million instead.

The commercial signal is weak. The accounts do not disclose turnover, so gross margin is the best public indicator of sales activity. It rose steadily to €593,692 in 2024 and then fell to €320,026 in 2025, the year the flagship device launched. Staff numbers fell with it.

Why Europe Should Care

On strategic fit, Perseus is close to a textbook case. Its grant came under the 2021 challenge for Strategic Digital and Health Technologies. In July 2025 the European Commission's life sciences strategy committed to fund "the development of microbiome-based solutions", and the accompanying flagship aims to make the EU "a world-class innovator in One Health microbiome-based solutions", backed by close to €100 million of Horizon Europe money in 2026 and 2027, as Human Microbiome Action reports. The European Biotech Act, proposed in December 2025, puts "easing access to funding, especially for start-ups and SMEs" among its core aims.

There is also a supply-chain argument. The company's CORDIS report describes the market as "heavily dominated by DNA sequencing players", and the best-known sequencing platforms come from outside the EU: Illumina is headquartered in San Diego and Oxford Nanopore outside Oxford in the United Kingdom. A European method that avoids sequencing altogether, with ZEISS as an early investor and a Belgian engineering firm building the hardware, is exactly the kind of technology the EU says it wants to keep at home.

The Verdict

Perseus Biomics has not been asked for comment for this article. This piece is based entirely on public records, company statements and published research, linked throughout.